Ruxolitinib Found to Cause Eyelash Growth: A Case Report

July 2017 in “ Journal of medical case reports ”

Julia Song, Alice Song, Trisa Palmares, Michael Song, Harold Song

ruxolitinib Janus kinase inhibitor eyelash growth madarosis hypereosinophilic syndrome Jakafi

Studysummary This study reports the first case of eyelash elongation and thickening in a patient with hypereosinophilic syndrome taking the Janus kinase inhibitor ruxolitinib. Our plain-language summary of this paper — not a Tressless recommendation.

In a 2017 case report, a 77-year-old Asian man with hypereosinophilic syndrome (HES) exhibited unexpected eyelash growth after treatment with ruxolitinib, an oral Janus kinase inhibitor. The patient, who did not respond to other medications, noticed his eyelashes becoming longer and thicker several months into the ruxolitinib treatment, with no hair growth on other body parts. This was the first report of eyelash growth associated with ruxolitinib, leading the authors to suggest that Janus kinase inhibitors might promote eyelash growth and could be investigated as a treatment for madarosis, the absence of eyelashes. The case underscores the potential side effect of eyelash growth from these drugs and their possible use in hair loss conditions.

View this study on jmedicalcasereports.biomedcentral.com →

Discuss this study in the Community →

Research cited in this study

12 / 12 results

research JAK Inhibitors in Dermatology: The Promise of a New Drug Class

355 citations , January 2017 in “Journal of the American Academy of Dermatology”

This review reports no new results and highlights existing research suggesting JAK inhibitors may be effective in treating inflammatory skin conditions like alopecia areata, atopic dermatitis, psoriasis, and vitiligo.

research Tofacitinib for the Treatment of Alopecia Areata and Variants in Adolescents

139 citations , November 2016 in “Journal of the American Academy of Dermatology”

In this retrospective review, tofacitinib treatment was associated with clinically significant hair regrowth in most adolescent patients with alopecia areata, though limitations suggest further studies are needed to confirm these findings.

research Tofacitinib for the Treatment of Severe Alopecia Areata and Variants: A Study of 90 Patients

238 citations , November 2016 in “Journal of The American Academy of Dermatology”

In this study, tofacitinib was reported to improve scalp hair regrowth in patients with severe alopecia areata, alopecia totalis, and alopecia universalis, showing a higher response in alopecia areata.

research Oral Ruxolitinib Induces Hair Regrowth in Patients with Moderate-to-Severe Alopecia Areata

196 citations , September 2016 in “JCI insight”

This study explored the effectiveness of the oral JAK1/2 inhibitor ruxolitinib in treating patients with moderate-to-severe alopecia areata, building on prior success with JAK inhibitors in mice, but results are not reported in this abstract.

research Rapid Skin Repigmentation on Oral Ruxolitinib in a Patient with Coexistent Vitiligo and Alopecia Areata

157 citations , December 2015 in “Journal of the American Academy of Dermatology”

This case study reported significant but temporary hair regrowth and skin repigmentation in a patient with vitiligo and alopecia areata during treatment with oral ruxolitinib.

research Topical Ruxolitinib for the Treatment of Alopecia Universalis

96 citations , December 2015 in “JAMA dermatology”

This article discusses the potential of topical ruxolitinib as a treatment for alopecia universalis and acknowledges the need for alternatives to systemic JAK inhibitors due to the risk of serious side effects.

research Alopecia Areata Is Driven by Cytotoxic T Lymphocytes and Is Reversed by JAK Inhibition

701 citations , August 2014 in “Nature medicine”

This study found that JAK inhibitors promote hair regrowth in both mice and human alopecia areata cases by blocking key immune pathways involved in disease development.

research Safety and Efficacy of Bimatoprost Solution 0.03% Topical Application in Patients with Chemotherapy-Induced Eyelash Loss

17 citations , December 2013 in “Journal of Investigative Dermatology Symposium Proceedings”

In this study, once-daily treatment with bimatoprost 0.03% solution significantly increased eyelash growth, thickness, and darkness in patients with chemotherapy-induced eyelash loss compared to placebo, and was well tolerated over one year.

Eyelash Preservation During Chemotherapy and Topical Prostaglandin Therapy

research Topical Prostaglandin F2α Analog Induced Poliosis

51 citations , May 2004 in “American journal of ophthalmology”

This study reports that poliosis can be an adverse effect of topical prostaglandin F2α analog therapy in patients treated for primary open angle glaucoma.